Cargando…
How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985759/ https://www.ncbi.nlm.nih.gov/pubmed/33557029 http://dx.doi.org/10.3390/curroncol28010077 |
_version_ | 1783668316061040640 |
---|---|
author | Zhu, Xiaofu Dent, Susan Paquet, Lise Zhang, Tinghua Tesolin, Daniel Graham, Nadine Aseyev, Olexiy Song, Xinni |
author_facet | Zhu, Xiaofu Dent, Susan Paquet, Lise Zhang, Tinghua Tesolin, Daniel Graham, Nadine Aseyev, Olexiy Song, Xinni |
author_sort | Zhu, Xiaofu |
collection | PubMed |
description | Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit of chemotherapy, we surveyed medical oncologists in Canada to assess their usage and perception of the ODX assay. Methods: A 34-item survey was distributed to Canadian medical oncologists via the Canadian Association of Medical Oncologists. Data was collected on physician demographics, ODX usage patterns, and physicians’ perception of the impact clinical and pathologic characteristics make on ODX utilization. Results: Response rate was 20.6% with 47 responses received from 228 survey sent. Forty-five responses were eligible for analysis. Sixty-two percent (28/45) of respondents treated predominantly breast cancer, and 60% (27/45) have been in practice for at least 10 years. The most cited reason for using ODX was to avoid giving patients unnecessary chemotherapy (64%; 29/45). Sixty-seven percent (30/45) deferred making treatment decisions until ODX testing was completed. Factors most strongly impacting ODX utilization included: patient request, medical comorbidities and tumor grade. In clinical scenarios, ODX was more frequently selected for patients aged 40–65 (vs. <40 or >65), grade 2 tumors (vs. grade 1 or 3), and Ki-67 index of 10–20% (vs. <10% or >20%). Conclusions: This survey demonstrated that Canadian medical oncologists are preferentially using ODX to avoid giving patients unnecessary chemotherapy. The utilization of ODX is mainly in patients with intermediate clinical and pathologic features. |
format | Online Article Text |
id | pubmed-7985759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79857592021-03-24 How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients Zhu, Xiaofu Dent, Susan Paquet, Lise Zhang, Tinghua Tesolin, Daniel Graham, Nadine Aseyev, Olexiy Song, Xinni Curr Oncol Article Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit of chemotherapy, we surveyed medical oncologists in Canada to assess their usage and perception of the ODX assay. Methods: A 34-item survey was distributed to Canadian medical oncologists via the Canadian Association of Medical Oncologists. Data was collected on physician demographics, ODX usage patterns, and physicians’ perception of the impact clinical and pathologic characteristics make on ODX utilization. Results: Response rate was 20.6% with 47 responses received from 228 survey sent. Forty-five responses were eligible for analysis. Sixty-two percent (28/45) of respondents treated predominantly breast cancer, and 60% (27/45) have been in practice for at least 10 years. The most cited reason for using ODX was to avoid giving patients unnecessary chemotherapy (64%; 29/45). Sixty-seven percent (30/45) deferred making treatment decisions until ODX testing was completed. Factors most strongly impacting ODX utilization included: patient request, medical comorbidities and tumor grade. In clinical scenarios, ODX was more frequently selected for patients aged 40–65 (vs. <40 or >65), grade 2 tumors (vs. grade 1 or 3), and Ki-67 index of 10–20% (vs. <10% or >20%). Conclusions: This survey demonstrated that Canadian medical oncologists are preferentially using ODX to avoid giving patients unnecessary chemotherapy. The utilization of ODX is mainly in patients with intermediate clinical and pathologic features. MDPI 2021-02-04 /pmc/articles/PMC7985759/ /pubmed/33557029 http://dx.doi.org/10.3390/curroncol28010077 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhu, Xiaofu Dent, Susan Paquet, Lise Zhang, Tinghua Tesolin, Daniel Graham, Nadine Aseyev, Olexiy Song, Xinni How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients |
title | How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients |
title_full | How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients |
title_fullStr | How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients |
title_full_unstemmed | How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients |
title_short | How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients |
title_sort | how canadian oncologists use oncotype dx for treatment of breast cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985759/ https://www.ncbi.nlm.nih.gov/pubmed/33557029 http://dx.doi.org/10.3390/curroncol28010077 |
work_keys_str_mv | AT zhuxiaofu howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients AT dentsusan howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients AT paquetlise howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients AT zhangtinghua howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients AT tesolindaniel howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients AT grahamnadine howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients AT aseyevolexiy howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients AT songxinni howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients |